Mahesh Narayanan - Immage Biotherapeutics COO and Director
Director
Mr. Mahesh Narayanan is Chief Operating Officer, Director of the Company. Mr. Narayanan was CEO of PepVax, Inc., a Bethesda biotechnology company, from February 2013 through current. Mr. Narayanan was an Independent Consultant for Life Science companies from September 2012 through February 2013. Mr. Narayanan was a Researcher at GlaxoSmithKline, a Pennsylvania pharmaceutical company, from January 2012 through September 2012. Mr. Narayanan was a Managing Consultant at Penn Biotech Group via Wharton School of Business from September 2010 through September 2012. since 2015.
| Age | 34 |
| Tenure | 9 years |
| Phone | 866-692-2939 |
| Web | http://www.immagebio.com |
Immage Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (4.9611) % which means that it has lost $4.9611 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.3357) %, meaning that it created substantial loss on money invested by shareholders. Immage Biotherapeutics' management efficiency ratios could be used to measure how well Immage Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kevin Bradicich | The Hanover Insurance | 63 | |
| Helen Hicks | Sun Life Financial | 60 | |
| Harriett Taggart | The Hanover Insurance | 73 | |
| Barbara Stymiest | Sun Life Financial | 64 | |
| Martin Hughes | The Hanover Insurance | 71 | |
| Dawn Lai | Sun Life Financial | N/A | |
| Jane Carlin | The Hanover Insurance | 65 | |
| Sara Lewis | Sun Life Financial | 52 | |
| Cynthia Day | Primerica | 55 | |
| Stephanie Coyles | Sun Life Financial | 54 | |
| Joseph Ramrath | The Hanover Insurance | 64 | |
| Martin Glynn | Sun Life Financial | 68 | |
| Kathleen Lane | The Hanover Insurance | 63 | |
| Jack Atkins | Old Dominion Freight | N/A | |
| Hugh Segal | Sun Life Financial | 68 | |
| Wendell Knox | The Hanover Insurance | 73 | |
| Theodore Bunting | The Hanover Insurance | 62 | |
| Scott Powers | Sun Life Financial | 61 | |
| Sanjeev Dheer | Primerica | 61 | |
| Joel Babbit | Primerica | 67 | |
| James Peck | Sun Life Financial | 56 | |
Management Performance
| Return On Equity | -11.34 | |||
| Return On Asset | -4.96 |
Immage Biotherapeutics Leadership Team
Elected by the shareholders, the Immage Biotherapeutics' board of directors comprises two types of representatives: Immage Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immage. The board's role is to monitor Immage Biotherapeutics' management team and ensure that shareholders' interests are well served. Immage Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immage Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Achinko, VP of Bioformatics | ||
| Mahesh Narayanan, COO and Director | ||
| CPA JD, CFO and Director | ||
| Zhi Mou, CEO and President Treasurer, Secretary and Director |
Immage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immage Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.34 | |||
| Return On Asset | -4.96 | |||
| Current Valuation | 32.93 K | |||
| Shares Outstanding | 151.74 M | |||
| Shares Owned By Insiders | 69.85 % | |||
| Price To Earning | (0.01) X | |||
| EBITDA | (1.82 M) | |||
| Net Income | (216.48 K) | |||
| Cash And Equivalents | 53.69 K | |||
| Debt To Equity | 2.52 % |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Immage Stock
If you are still planning to invest in Immage Biotherapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immage Biotherapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |